We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hinting that it may be time to get tougher with delinquents, the Senate Finance Committee is demanding an investigation into drug companies responsible for overcharging federal health programs for pharmaceuticals.
Granting law enforcement agencies the authority to destroy drugs illegally shipped into the U.S. at the point of import would go a long way toward lightening the load of policing illicit internet drug purchases, representatives from several U.S. law enforcement agencies said.
A rule proposed last week would dramatically affect the amount Medicare pays for prescription drugs, in some cases lowering the cost to the government by as much as 89 percent.
A new study released this week indicates that the Medicare-approved drug discount cards provide significant savings compared to retail prices paid by cash customers.
The Senate Finance Committee is demanding an investigation into drug companies responsible for overcharging federal health programs for pharmaceuticals; the committee is also hinting that it may be time to get tougher with delinquents.
The Centers for Medicare & Medicaid Services (CMS) released a proposed rule yesterday that would dramatically affect the amount Medicare pays for prescription drugs — in some cases lowering the cost to the government by as much as 89 percent.
Proposed regulations implementing the prescription drug savings available through the Medicare discount drug card were announced by HHS Secretary Tommy Thompson yesterday.
The ranking Democrat on the House Government Reform Committee has asked the FDA to release summaries of pediatric studies on the use of antidepressants and other drugs that the agency may be withholding.
The Centers for Medicare & Medicaid Services (CMS) will revise its Medicare coverage policy to remove barriers that prevent antiobesity treatments from being covered.
A ranking Democratic congressman has asked the FDA to immediately release summaries of studies on pediatric use of antidepressants and other drugs that the agency has withheld to date.